Importantly, current international guidelines, including those of the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO), recommend the separate immunohistochemical evaluation of MLH1, PMS2, MSH2, and MSH6 in colorectal cancer [36,37]. The gene discussed is MLH1; the disease is colorectal cancer.